EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tripartite motif 38 alleviates the pathological process of NAFLD–NASH by promoting TAB2 degradation

Xinxin Yao, Ruixiang Dong, Sha Hu, Zhen Liu, Jie Cui, Fengjiao Hu, Xu Cheng, Xiaoming Wang, Tengfei Ma, Song Tian, Xiao-Jing Zhang, Yufeng Hu und 3 weitere

Journal of Lipid Research · 2023

DOI: 10.1016/j.jlr.2023.100382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2023. Verfasst von Xinxin Yao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Wuhan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, without any Food and Drug Administration-approved pharmacological intervention in clinic. Trim38, as an important member of the TRIM (tripartite motif-containing) family, was largely reported to be involved in the regulation of innate immune and inflammatory responses. However, the functional roles of TRIM38 in NAFLD remain largely unknown. Here, the expression of TRIM38 was first detected in liver samples of both NAFLD mice model and patients diagnosed with NAFLD. We found that TRIM38 expression was downregulated in NAFLD liver tissues compared with normal liver tissues. Genetic Trim38-KO in vivo showed that TRIM38 depletion deteriorated the high-fat diet and high fat and high cholesterol diet-induced hepatic steatosis and high fat and high cholesterol diet-induced liver inflammation and fibrosis. In particular, we found that the effects of hepatocellular lipid accumulation and inflammation induced by palmitic acid and oleic acid were aggravated by TRIM38 depletion but mitigated by TRIM38 overexpression in vitro. Mechanically, RNA-Seq analysis demonstrated that TRIM38 ameliorated nonalcoholic steatohepatitis progression by attenuating the activation of MAPK signaling pathway. We further found that TRIM38 interacted with transforming growth factor-β-activated kinase 1 binding protein 2 and promoted its protein degradation, thus inhibiting the transforming growth factor-β-activated kinase 1-MAPK signal cascades. In summary, our study revealed that TRIM38 could suppress hepatic steatosis, inflammatory, and fibrosis in NAFLD via promoting transforming growth factor-β-activated kinase 1 binding protein 2 degradation. TRIM38 could be a potential target for NAFLD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseAnimalsMiceCarrier ProteinsCholesterolDiet, High-FatLiverMAP Kinase Signaling SystemMice, Inbred C57BLSignal TransductionTripartite Motif ProteinsUbiquitin-Protein LigasesAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

MAPKNAFLDTAB2TRIM38hepatic steatosismetabolism disorder

Substanzen

Carrier ProteinsCholesterolTripartite Motif ProteinsUbiquitin-Protein LigasesTRIM38 protein, mouseTab2 protein, mouseAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China.
  • Institute of Model Animal, Wuhan University, Wuhan, China.
  • Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China.
  • Institute of Model Animal, Wuhan University, Wuhan, China; Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Gannan Innovation and Translational Medicine Research Institute, Ganzhou, China; Key Laboratory of Cardiovascular Disease Prevention and Control, Ministry of Education, First Affiliated Hospital of Gannan Medical Univer…
  • Department of Neurology, Huanggang Central Hospital, Huanggang, China.

Förderung

  • National Natural Science Foundation of China
  • Wuhan University

Zitieren

APA

Yao, X., Dong, R., Hu, S., Liu, Z., Cui, J., Hu, F., Cheng, X., Wang, X., Ma, T., Tian, S., Zhang, X. J., Hu, Y., Bai, L., Li, H., & Zhang, P. (2023). Tripartite motif 38 alleviates the pathological process of NAFLD–NASH by promoting TAB2 degradation. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2023.100382

Vancouver

Yao X, Dong R, Hu S, Liu Z, Cui J, Hu F, et al. Tripartite motif 38 alleviates the pathological process of NAFLD–NASH by promoting TAB2 degradation. Journal of Lipid Research. 2023. doi:10.1016/j.jlr.2023.100382

BibTeX
@article{Yao2023,
  author = {Yao, Xinxin and Dong, Ruixiang and Hu, Sha and Liu, Zhen and Cui, Jie and Hu, Fengjiao and Cheng, Xu and Wang, Xiaoming and Ma, Tengfei and Tian, Song and Zhang, Xiao-Jing and Hu, Yufeng and Bai, Lan and Li, Hongliang and Zhang, Peng},
  title = {Tripartite motif 38 alleviates the pathological process of NAFLD–NASH by promoting TAB2 degradation},
  journal = {Journal of Lipid Research},
  year = {2023},
  doi = {10.1016/j.jlr.2023.100382}
}
Kostenlos starten →